Mitraclip XTR vs. Pascal Transcatheter Valve Repair System for Edge-to-Edge Repair of Severe Tricuspid Regurgitation

Braun, Daniel; Löw, Kornelia; Orban, Mathias; Mehr, Michael; Gmeiner, Jonas; Maßberg, Steffen; Näbauer, Michael; Hausleiter, Jöerg

doi:10.1016/s0735-1097(20)31762-9

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a recent review on coaptation devices 52 which discussed the limited literature on the outcomes from each of these devices. This showed the first comparative study 53 between the Mitraclip and Pascal techniques, concluding similar results between both. Further comparative studies and studies focusing on the TV are required.…”

Section: Management Of Tricuspid Diseasesupporting

confidence: 63%

Tricuspid valve diseases: Interventions on the forgotten heart valve

Yoganathan

Khan

et al. 2020

J Card Surg

View full text Add to dashboard Cite

Over the past few decades, the tricuspid valve (TV) interventions have been relatively lower compared to other cardiac valvular disease in terms of pathophysiology and management, especially regarding surgical intervention and therapy. However, recent crucial advances in assessment and management of the TV disease have resulted in a renewed interest in the "forgotten valve." The medical treatment aims to cure the underlying disease and address the presentation of the right heart failure. Surgical interventions have proven to yield good outcomes for those for whom surgery is indicated. For those who are not suitable for surgery, transcatheter surgery may prove to be a suitable replacement. Best practice with regard to surgical techniques is still in question due to limited data. This has been slowing the introduction of transcatheter interventions into common practical guidelines. The aim of this literature review is to discuss new insights on the pathophysiology, diagnosis, and interventions of TV disease, highlighting the surgical management and emerging transcatheter therapies. In addition, this review will provide an overview of the current state of the literature surrounding TV interventions and providing suggestions for future directives.

show abstract

Section: Management Of Tricuspid Diseasesupporting

confidence: 63%

Tricuspid valve diseases: Interventions on the forgotten heart valve

Yoganathan

Khan

et al. 2020

J Card Surg

View full text Add to dashboard Cite

show abstract

“…There are currently four categories of TTVI, which are at various developmental stages: coaptation devices (TriClip ® , Pascal ® , Dragonfly ® , FORMA ® ), annuloplasty devices Greater Tricuspid Regurgitation (TRILUMINATE) meeting its primary endpoint. [18][19] Although several non-randomized controlled trials (RCT's) [20][21][22][23][24][25][26][27] using various types of TTVI devices showed symptomatic relief, the ideal timing of intervention to impact survival remains to be defined. [28][29] The TRILUMINATE study on tricuspid edge-to-edge repair is the only RCT testing a TTVI device.…”

Section: Discussionmentioning

confidence: 99%

Most hospitalized patients with significant tricuspid regurgitation have advanced disease preventing transcatheter tricuspid valve intervention

Dumitriu Carcoana,

Scoma,

Maletz

et al. 2024

Cardiovascular Revascularization Medicine

View full text Add to dashboard Cite

“…In this study published by Braun et al, in which 88 patients were treated with the MitraClip and 32 received the PASCAL system, no differences were observed between the two devices in terms of success of the procedure, the reduction of TR or detachment of the device (11% with MitraClip versus 6% with PAS-CAL). The authors concluded that both devices are similar in terms of efficacy and safety in reducing TR [38].…”

Section: Percutaneous Coaptation Devicesmentioning

confidence: 96%

Percutaneous Treatment of Tricuspid Regurgitation

Minguito‐Carazo¹,

Benito‐González²,

Estévez‐Loureiro³

et al. 2021

Interventional Treatment for Structural Heart Disease

View full text Add to dashboard Cite

Tricuspid valve regurgitation is one of the most common valvular disorders and moderate to severe tricuspid regurgitation is consistently associated to an increased morbidity and mortality. From an etiopathological perspective, tricuspid regurgitation can be classified in primary, due to the organic disease of any of the valve components, or secondary, as a result of tricuspid valve annulus dilatation, adverse right ventricular remodeling and tricuspid valve leaflet tethering. Despite its poor prognosis, most patients with tricuspid insufficiency are managed conservatively and only those with concomitant left heart valvular disease do finally go surgery in the real-world setting. In fact, outcomes of conventional surgery in patients with isolated tricuspid regurgitation are poor and this approach has not proven yet any survival benefit over stand-alone medical therapy. Given this unmet need, new transcatheter techniques have been developed in the last years, including leaflet plication, percutaneous annuloplasty and valve implantation in either the tricuspid position (orthotopic implantation) or in a different position such as the vena cava (heterotopic implantation). These techniques, with promising outcomes, are seen as an interesting alternative to open-heart surgery given the much lower periprocedural risk.

show abstract

Mitraclip XTR vs. Pascal Transcatheter Valve Repair System for Edge-to-Edge Repair of Severe Tricuspid Regurgitation

Cited by 5 publications

References 0 publications

Tricuspid valve diseases: Interventions on the forgotten heart valve

Tricuspid valve diseases: Interventions on the forgotten heart valve

Most hospitalized patients with significant tricuspid regurgitation have advanced disease preventing transcatheter tricuspid valve intervention

Percutaneous Treatment of Tricuspid Regurgitation

Contact Info

Product

Resources

About